Literature DB >> 23981364

Interaction of nonsteroidal anti-inflammatory drugs with membranes: in vitro assessment and relevance for their biological actions.

Catarina Pereira-Leite1, Cláudia Nunes, Salette Reis.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs in the world due to their anti-inflammatory, analgesic and antipyretic properties. Nevertheless, the consumption of these drugs is still associated with the occurrence of a wide spectrum of adverse effects. Regarding the major role of membranes in cellular events, the hypothesis that the biological actions of NSAIDs may be related to their effect at the membrane level has triggered the in vitro assessment of NSAIDs-membrane interactions. The use of membrane mimetic models, cell cultures, a wide range of experimental techniques and molecular dynamics simulations has been providing significant information about drugs partition and location within membranes and also about their effect on diverse membrane properties. These studies have indeed been providing evidences that the effect of NSAIDs at membrane level may be an additional mechanism of action and toxicity of NSAIDs. In fact, the pharmacokinetic properties of NSAIDs are closely related to the ability of these drugs to interact and overcome biological membranes. Moreover, the therapeutic actions of NSAIDs may also result from the indirect inhibition of cyclooxygenase due to the disturbing effect of NSAIDs on membrane properties. Furthermore, increasing evidences suggest that the disordering effects of these drugs on membranes may be in the basis of the NSAIDs-induced toxicity in diverse organ systems. Overall, the study of NSAIDs-membrane interactions has proved to be not only important for the better understanding of their pharmacological actions, but also for the rational development of new approaches to overcome NSAIDs adverse effects.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ATP; Biological membranes; COX; COX-2 selective inhibitors; CV; Coxibs; DPPC; GI; GUVs; LB; LOX; LUVs; Langmuir-Blodgett; MD; MLVs; Membrane model systems; NO-NSAIDs; NSAIDs; Nonsteroidal anti-inflammatory drugs; PC-NSAIDs; PG; Pharmacokinetic properties; SLB; SUVs; Therapeutic and toxic actions; Tx; adenosine triphosphate; cardiovascular; cyclooxygenase; dipalmitoylphosphatidylcholine; gastrointestinal; giant unilamellar vesicles; large unilamellar vesicles; lipoxygenase; mPGES-1; microsomal prostaglandin E synthase-1; molecular dynamics; multilamellar lipid vesicles; nitric oxide-releasing nonsteroidal anti-inflammatory drugs; nonsteroidal anti-inflammatory drugs; phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs; prostaglandin; small unilamellar vesicles; supported lipid bilayers; thromboxane

Mesh:

Substances:

Year:  2013        PMID: 23981364     DOI: 10.1016/j.plipres.2013.08.003

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  16 in total

1.  Dynamic analysis of phospholipid metabolism of mouse macrophages treated with common non-steroidal anti-inflammatory drugs.

Authors:  Haibo Peng; Xia Wu; Lifang Zhao; Yifan Feng
Journal:  Mol Cell Biochem       Date:  2015-10-06       Impact factor: 3.396

Review 2.  NSAIDs: learning new tricks from old drugs.

Authors:  Federico Díaz-González; Francisco Sánchez-Madrid
Journal:  Eur J Immunol       Date:  2015-01-21       Impact factor: 5.532

3.  The Molecular Structure of Human Red Blood Cell Membranes from Highly Oriented, Solid Supported Multi-Lamellar Membranes.

Authors:  Sebastian Himbert; Richard J Alsop; Markus Rose; Laura Hertz; Alexander Dhaliwal; Jose M Moran-Mirabal; Chris P Verschoor; Dawn M E Bowdish; Lars Kaestner; Christian Wagner; Maikel C Rheinstädter
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

4.  Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers.

Authors:  Elena Rykova; Aleksey Sizikov; Dirk Roggenbuck; Oksana Antonenko; Leonid Bryzgalov; Evgeniy Morozkin; Kseniya Skvortsova; Valentin Vlassov; Pavel Laktionov; Vladimir Kozlov
Journal:  Arthritis Res Ther       Date:  2017-05-02       Impact factor: 5.156

Review 5.  Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications.

Authors:  Angela P Cadavid
Journal:  Front Immunol       Date:  2017-03-15       Impact factor: 7.561

6.  Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicans.

Authors:  Helene Tournu; Jennifer Carroll; Brian Latimer; Ana-Maria Dragoi; Samantha Dykes; James Cardelli; Tracy L Peters; Karen E Eberle; Glen E Palmer
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

7.  Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.

Authors:  Tülay Bakirel; Fulya Üstün Alkan; Oya Üstüner; Suzan Çinar; Funda Yildirim; Gaye Erten; Utku Bakirel
Journal:  J Vet Med Sci       Date:  2016-01-29       Impact factor: 1.267

8.  Teicoplanin-Modified HPLC Column as a Source of Experimental Parameters for Prediction of the Anticonvulsant Activity of 1,2,4-Triazole-3-Thiones by the Regression Models.

Authors:  Jolanta Flieger; Anna Orzeł; Anna Kowalska-Kępczyńska; Magdalena Pizoń; Hanna Trębacz; Dariusz Majerek; Tomasz Plech; Wojciech Płaziński
Journal:  Materials (Basel)       Date:  2020-06-10       Impact factor: 3.623

Review 9.  Interdisciplinary Approach to the Temporomandibular Joint Osteoarthritis-Review of the Literature.

Authors:  Marcin Derwich; Maria Mitus-Kenig; Elzbieta Pawlowska
Journal:  Medicina (Kaunas)       Date:  2020-05-09       Impact factor: 2.430

10.  Structural Similarity with Cholesterol Reveals Crucial Insights into Mechanisms Sustaining the Immunomodulatory Activity of the Mycotoxin Alternariol.

Authors:  Giorgia Del Favero; Raphaela M Mayer; Luca Dellafiora; Lukas Janker; Laura Niederstaetter; Chiara Dall'Asta; Christopher Gerner; Doris Marko
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.